Cargando…
Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
PURPOSE: Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive therapy option for inoperable liver oligometastases. Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had undergone ultrasound-guided breath-hold SABR. PATIENTS AND METHODS: 19 pat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464721/ https://www.ncbi.nlm.nih.gov/pubmed/22710033 http://dx.doi.org/10.1186/1748-717X-7-92 |
_version_ | 1782245462106963968 |
---|---|
author | Boda-Heggemann, Judit Dinter, Dietmar Weiss, Christel Frauenfeld, Anian Siebenlist, Kerstin Attenberger, Ulrike Ottstadt, Martine Schneider, Frank Hofheinz, Ralf-Dieter Wenz, Frederik Lohr, Frank |
author_facet | Boda-Heggemann, Judit Dinter, Dietmar Weiss, Christel Frauenfeld, Anian Siebenlist, Kerstin Attenberger, Ulrike Ottstadt, Martine Schneider, Frank Hofheinz, Ralf-Dieter Wenz, Frederik Lohr, Frank |
author_sort | Boda-Heggemann, Judit |
collection | PubMed |
description | PURPOSE: Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive therapy option for inoperable liver oligometastases. Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had undergone ultrasound-guided breath-hold SABR. PATIENTS AND METHODS: 19 patients with liver metastases of various primary tumors consecutively treated with SABR (image-guidance with stereotactic ultrasound in combination with computer-controlled breath-hold) were analysed regarding overall-survival (OS), progression-free-survival (PFS), progression pattern, local control (LC), acute and late toxicity. RESULTS: PTV (planning target volume)-size was 108 ± 109cm(3) (median 67.4 cm(3)). BED2 (Biologically effective dose in 2 Gy fraction) was 83.3 ± 26.2 Gy (median 78 Gy). Median follow-up and median OS were 12 months. Actuarial 2-year-OS-rate was 31%. Median PFS was 4 months, actuarial 1-year-PFS-rate was 20%. Site of first progression was predominantly distant. Regression of irradiated lesions was observed in 84% (median time to detection of regression was 2 months). Actuarial 6-month-LC-rate was 92%, 1- and 2-years-LC-rate 57%, respectively. BED2 influenced LC. When a cut-off of BED2 = 78 Gy was used, the higher BED2 values resulted in improved local control with a statistical trend to significance (p = 0.0999). Larger PTV-sizes, inversely correlated with applied dose, resulted in lower local control, also with a trend to significance (p-value = 0.08) when a volume cut-off of 67 cm(3) was used. No local relapse was observed at PTV-sizes < 67 cm(3) and BED2 > 78 Gy. No acute clinical toxicity > °2 was observed. Late toxicity was also ≤ °2 with the exception of one gastrointestinal bleeding-episode 1 year post-SABR. A statistically significant elevation in the acute phase was observed for alkaline-phosphatase; in the chronic phase for alkaline-phosphatase, bilirubine, cholinesterase and C-reactive protein. CONCLUSIONS: A trend to statistically significant correlation of local progression was observed for BED2 and PTV-size. Dose-levels BED2 > 78 Gy cannot be reached in large lesions constituting a significant fraction of this series. Image-guided SABR (igSABR) is therefore an effective non-invasive treatment modality with low toxicity in patients with small inoperable liver metastases. |
format | Online Article Text |
id | pubmed-3464721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34647212012-10-05 Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results Boda-Heggemann, Judit Dinter, Dietmar Weiss, Christel Frauenfeld, Anian Siebenlist, Kerstin Attenberger, Ulrike Ottstadt, Martine Schneider, Frank Hofheinz, Ralf-Dieter Wenz, Frederik Lohr, Frank Radiat Oncol Research PURPOSE: Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive therapy option for inoperable liver oligometastases. Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had undergone ultrasound-guided breath-hold SABR. PATIENTS AND METHODS: 19 patients with liver metastases of various primary tumors consecutively treated with SABR (image-guidance with stereotactic ultrasound in combination with computer-controlled breath-hold) were analysed regarding overall-survival (OS), progression-free-survival (PFS), progression pattern, local control (LC), acute and late toxicity. RESULTS: PTV (planning target volume)-size was 108 ± 109cm(3) (median 67.4 cm(3)). BED2 (Biologically effective dose in 2 Gy fraction) was 83.3 ± 26.2 Gy (median 78 Gy). Median follow-up and median OS were 12 months. Actuarial 2-year-OS-rate was 31%. Median PFS was 4 months, actuarial 1-year-PFS-rate was 20%. Site of first progression was predominantly distant. Regression of irradiated lesions was observed in 84% (median time to detection of regression was 2 months). Actuarial 6-month-LC-rate was 92%, 1- and 2-years-LC-rate 57%, respectively. BED2 influenced LC. When a cut-off of BED2 = 78 Gy was used, the higher BED2 values resulted in improved local control with a statistical trend to significance (p = 0.0999). Larger PTV-sizes, inversely correlated with applied dose, resulted in lower local control, also with a trend to significance (p-value = 0.08) when a volume cut-off of 67 cm(3) was used. No local relapse was observed at PTV-sizes < 67 cm(3) and BED2 > 78 Gy. No acute clinical toxicity > °2 was observed. Late toxicity was also ≤ °2 with the exception of one gastrointestinal bleeding-episode 1 year post-SABR. A statistically significant elevation in the acute phase was observed for alkaline-phosphatase; in the chronic phase for alkaline-phosphatase, bilirubine, cholinesterase and C-reactive protein. CONCLUSIONS: A trend to statistically significant correlation of local progression was observed for BED2 and PTV-size. Dose-levels BED2 > 78 Gy cannot be reached in large lesions constituting a significant fraction of this series. Image-guided SABR (igSABR) is therefore an effective non-invasive treatment modality with low toxicity in patients with small inoperable liver metastases. BioMed Central 2012-06-18 /pmc/articles/PMC3464721/ /pubmed/22710033 http://dx.doi.org/10.1186/1748-717X-7-92 Text en Copyright ©2012 Boda-Heggemann et al.;licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Boda-Heggemann, Judit Dinter, Dietmar Weiss, Christel Frauenfeld, Anian Siebenlist, Kerstin Attenberger, Ulrike Ottstadt, Martine Schneider, Frank Hofheinz, Ralf-Dieter Wenz, Frederik Lohr, Frank Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results |
title | Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results |
title_full | Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results |
title_fullStr | Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results |
title_full_unstemmed | Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results |
title_short | Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results |
title_sort | hypofractionated image-guided breath-hold sabr (stereotactic ablative body radiotherapy) of liver metastases – clinical results |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464721/ https://www.ncbi.nlm.nih.gov/pubmed/22710033 http://dx.doi.org/10.1186/1748-717X-7-92 |
work_keys_str_mv | AT bodaheggemannjudit hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT dinterdietmar hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT weisschristel hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT frauenfeldanian hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT siebenlistkerstin hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT attenbergerulrike hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT ottstadtmartine hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT schneiderfrank hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT hofheinzralfdieter hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT wenzfrederik hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults AT lohrfrank hypofractionatedimageguidedbreathholdsabrstereotacticablativebodyradiotherapyoflivermetastasesclinicalresults |